Website
News25/Ratings1
News · 26 weeks30+200%
2025-10-262026-04-19
Mix890d
- Market7(88%)
- SEC Filings1(13%)
Latest news
25 items- NEWSDeadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricidesSHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments that its drug candidate NV-387 is the weapon necessary for combatting growing cases of deadly measles worldwide.Bangladesh recently reported 18,219 suspected measles cases, including 2,897 confirmed cases, and 164 suspected case deaths, with transmission in 58 of 64 districts, in the single month of March 15 to April 14, 2026[1]. Over 80% of the cases are in children under the age of 5 years, and
- NEWSMeasles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricidesSHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.NanoViricides will be e
- NEWSPhase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricidesSHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic Republic of Congo (DRC).Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research Pvt. Ltd., and associates in DRC. The CRO personnel are expected to visit the Site for final preparations and for staff training in the first week of April, 2026. Enrollment and dosing of patients is expected to begin after the staff training is completed.The Company previously reported that it has received approval to start said Phase II Clinical Trial o
- NEWSNanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is CompleteSHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce that it will be presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, Florida.NanoViricides announces herewith that the manufacture of the drug product for this clinical trial, "NV-387 Oral Gummies" is now complete, in anticipation of starting dosing in patients as soon as site readiness is established.Anil R. Diwan, PhD, President and Executive Chairman of the Company will deliver a company presentation on Thursday, March 12th at 11:50 am ET, and wi
- SECSEC Form 10-Q filed by NanoViricides Inc.10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSMPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricidesSHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for Orphan Drug Designation (ODD) for "NV-387 as a Treatment for MPox" with the US FDA Office of Orphan Products Development (OOPD).If approved, orphan drug designation will qualify NanoViricides for incentives including:Tax credits for qualified clinical trials;Exemption from certain user fees;Potential seven years of market exclusivity after a
- NEWSMeasles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricidesSHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Orphan Drug Designation" (ODD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD).If approved, orphan drug designation will qualify NanoViricides for incentives including:Tax credits for qualified clinical trials;Exemption from certain user fees;Potential seven years of market exclusivity afte
- NEWSNanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam TorresSHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that our President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast by Mr. Adam Torres. The interview video is available at https://youtu.be/nU_2dgd-u1g.Mr. Torres began with asking what is the mission of NanoViricides. Dr. Diwan responded that NanoViricides was founded to revolutionize treatment of antiviral diseases the way penicillin revolutionized the treatment of bacterial infections.Dr. Diwan explained the technology behind navoviricides d
- NEWSDealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's EventATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.Below is the current list of companies confirmed to present and take meetings. Publ
- NEWSNanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, declares that the current severe influenza wave demonstrates the clear need for broad-spectrum antivirals that can work against all influenza viruses, as well as the seasonal respiratory viruses including RSV and Coronaviruses.This year has been a "moderately severe" flu season according to CDC. The new subclade K variant of Influenza A/H3N2 is causing more than 80% of the cases. CDC estimates that there have been at least 15,000,000 illnesses, 180,000 hospitalizations, and 7,
- SECSEC Form 424B3 filed by NanoViricides Inc.424B3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form EFFECT filed by NanoViricides Inc.EFFECT - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form DEL AM filed by NanoViricides Inc.DEL AM - NANOVIRICIDES, INC. (0001379006) (Filer)
- ANALYSTAlliance Global Partners initiated coverage on NanoViricidesAlliance Global Partners initiated coverage of NanoViricides with a rating of Buy
- SECSEC Form S-3 filed by NanoViricides Inc.S-3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and MeaslesSHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has signed a Master Services Agreement (MSA) with Only Orphans Cote, LLC, ("OOC") a regulatory consultant firm founded by Dr. Timothy Cote. Dr. Cote and OOC will help the Company formulate its orphan drug strategy for NV-387, as well as develop relevant orphan drug designation applications and prosecute these applications at the US FDA Office of Orphan Products."In
- SECNanoViricides Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal PositionSHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925112608/nnvc-20250930x10q.htm).Clinical Stage NV-387, a Single Drug, Meets Many Unmet Medical Needs in Viral DiseasesNV-387, based on a novel mechanism of action, and a novel nanomedicine technology that defines a new class of drugs, is a first-in-class broad-spectrum antiviral drug.Virus
- SECNanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form 10-Q filed by NanoViricides Inc.10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Friday, November 14th, at 11:25am ET at the Pharma Partnering Summit 2025 held at the Hilton Boston Logan Airport in Boston, MA.Event Information:EventNanoViricides Presentation at the Pharma Partnering Summit 2025 in Boston, MATime & Date11:25 am to 11:45 am ET on Friday, November 14, 2025LocationHilton Boston Logan Airport, Boston, MAAnil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the
- NEWSNanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market CloseSHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,571,429 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.68 per share in a registered direct offering (the "Offering"). The gross proceeds from the Offering are approximately $6 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company has issued and sold Series A warrants to purchase up to 3,
- SECSEC Form 424B5 filed by NanoViricides Inc.424B5 - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form 424B5 filed by NanoViricides Inc.424B5 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market CloseSHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,571,429 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.68 per share in a registered direct offering (the "Offering"). The gross proceeds from the Offering are expected to be approximately $6 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell Series A warrants to purchase up to